Evidence map›Paper›PMID 41881847›Full record

ArticleCancer discovery2026

Machine Learning Predicts Hepatocellular Carcinoma Risk from Routine Clinical Data: A Large Population-Based Multicentric Study.

Jan Clusmann, Paul-Henry Koop, David Y Zhang, Felix van Haag, Omar S M El Nahhas, Tobias Seibel, Laura Žigutytė, Apichat Kaewdech, Julien Calderaro, Frank Tacke and 6 more

Abstract readMulticenter Study
In one paragraph

Article in Cancer discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jan ClusmannDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.ORCID 0000-0003-2925-8438
Paul-Henry KoopDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.ORCID 0009-0004-2846-703X
David Y ZhangDepartment of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0003-1377-9829
Felix van HaagDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.ORCID 0009-0007-4586-7133
Omar S M El NahhasElse Kroener Fresenius Center for Digital Health, Technical University Dresden, Dresden, Germany.ORCID 0000-0002-2542-2117
Tobias SeibelDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.ORCID 0009-0004-9115-3228
Laura ŽigutytėElse Kroener Fresenius Center for Digital Health, Technical University Dresden, Dresden, Germany.ORCID 0009-0000-2447-2959
Apichat KaewdechGastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.ORCID 0000-0002-4058-5977
Julien CalderaroINSERM, IMRB, Université Paris Est Créteil, Créteil, France.ORCID 0000-0002-5370-0807
Frank TackeDepartment of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.ORCID 0000-0001-6206-0226
Tom LueddeDepartment for Gastroenterology, Hepatology and Infectiology, University Hospital Düsseldorf, Düsseldorf, Germany.ORCID 0000-0002-6288-8821
Daniel TruhnDepartment of Diagnostic and Interventional Radiology, University Hospital Aachen, Aachen, Germany.ORCID 0000-0002-9605-0728
Tony BrunsDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.ORCID 0000-0002-5576-6914
Kai Markus SchneiderDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.ORCID 0000-0002-0047-3794
Jakob Nikolas Kather *Else Kroener Fresenius Center for Digital Health, Technical University Dresden, Dresden, Germany.ORCID 0000-0002-3730-5348
Carolin V Schneider *Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.ORCID 0000-0002-6728-9246

Funding

Breast Cancer Research Foundation (BCRF) BCRF-25-225 (BELLADONNA)Bundesministerium für Forschung, Technologie und Raumfahrt (BMBF) 01EO2101Bundesministerium für Forschung, Technologie und Raumfahrt (BMBF) 01KD2104CBundesministerium für Forschung, Technologie und Raumfahrt (BMBF) 01KD2420ABundesministerium für Forschung, Technologie und Raumfahrt (BMBF) 01KT2302Bundesministerium für Forschung, Technologie und Raumfahrt (BMBF) 01ZU2402ABundesministerium für Forschung, Technologie und Raumfahrt (BMBF) 031L0312BBundesministerium für Forschung, Technologie und Raumfahrt (BMBF) 031L0315ABundesministerium für Forschung, Technologie und Raumfahrt (BMBF) 16DKZ2044ABundesministerium für Gesundheit (BMG) 2520DAT111 (DEEP LIVER)Deutsche Forschungsgemeinschaft (DFG) B07)Deutsche Forschungsgemeinschaft (DFG) CRC/TR 412 (535081457)Deutsche Forschungsgemeinschaft (DFG) Project-ID 403224013 (A11/B09Deutsche Forschungsgemeinschaft (DFG) SFB 1382 -Deutsche Forschungsgemeinschaft (DFG) SFB 1709/1 (533056198)Deutsche Krebshilfe (German Cancer Aid) 70115166Deutsche Krebshilfe (German Cancer Aid) 70115730European Research Council (ERC) 101114631 (NADIR)Gemeinsame Bundesausschuss (G-BA) 01VSF21048 (TransplantKI)German Academic Exchange Service (DAAD) 57616814 (SECAI)German Federal Ministry of Education and Research 01KD2215AGerman Federal Ministry of Education and Research SWAGGerman Federal Ministry of Research, Technology and Space BMFTR 031L0312AGerman Federal Ministry of Research, Technology and Space BMFTR RANSFORM LIVERHORIZON EUROPE Framework Programme (Horizon Europe) 101057091 (ODELIA)HORIZON EUROPE Framework Programme (Horizon Europe) 101096312 (GENIAL)Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen (MKW)National Heart, Lung, and Blood Institute (NHLBI) F30HL172382National Institute for Health and Care Research (NIHR) NIHR203331RWTH Aachen University (RWTH Aachen)
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a highly fatal tumor, for which risk stratification is crucial yet remains challenging. In this study, we develop an interpretable machine learning (ML) framework for HCC risk stratification based on routinely collected clinical data. We utilize prospectively collected multimodal data from more than 900,000 individuals and 983 cases of HCC across two population-scale cohorts: the UK Biobank study (development) and the All of Us Research Program (external testing). We assess individual and cumulative contributions of data modalities, including demographics, lifestyle, health records, blood, genomics, and metabolomics. Our final random forest-based models significantly outperform all publicly available state-of-the-art risk scores on both internal and external test sets. We demonstrate robustness across ethnic subgroups, provide comprehensive interpretability, and release all code, model weights, and a web calculator for external validation and agentic integration. Our study presents PRE-Screen-HCC, a robust and interpretable ML framework for HCC risk stratification and early detection. SIGNIFICANCE: Using data from population-scale cohorts, we develop and externally validate an ML framework for HCC risk stratification. Models trained on routine clinical data outperform published scores, perform on par with metabolomics and genomics, generalize across subgroups, and remain interpretable. See related commentary by Foda, p. 1252.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMachine LearningAgedFemaleHumansMaleMiddle AgedPredictive Learning ModelsRisk AssessmentRisk Factors

Identifiers

PMID41881847
PMCPMC13320177

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.